Profile data is unavailable for this security.
About the company
CSPC Pharmaceutical Group Ltd is an investment holding company primarily engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through three segments. The Finished Drugs segment in engaged in the research and development, manufacture and sale of pharmaceutical products and licensing business. The Bulk Products segment is engaged in the manufacture and sale of vitamin C, and antibiotic products in bulk powder form. The Functional Food and Others segment is engaged in the manufacture and sale of functional food products (including caffeine food additives, anhydrous glucose, acarbose and vitamin C buccal tablets), provision of healthcare service and others. The Company’s product therapeutic areas include nervous system, oncology, anti-infectives, cardiovascular, respiratory system, digestion and metabolism and others. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)29.79bn
- Net income in HKD4.62bn
- Incorporated1992
- Employees19.27k
- LocationCSPC Pharmaceutical Group LtdNo.896 Zhongshandong StreetGaoxin DistrictSHIJIAZHUANG 050035ChinaCHN
- Phone+86 31 187037015
- Fax+86 31 187039608
- Websitehttps://www.cspc.com.hk/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Industria Chmc Frmctc SpA | 23.16bn | 3.67bn | 90.92bn | 4.58k | 24.43 | 5.09 | 16.37 | 3.93 | 1.96 | 1.96 | 12.40 | 9.42 | 0.5377 | 1.81 | 4.87 | 557,416.80 | 8.51 | 10.50 | 10.71 | 13.46 | 67.66 | 69.89 | 15.83 | 19.98 | 1.16 | 8.30 | 0.5651 | 36.98 | 12.45 | 9.58 | 7.01 | 2.46 | 13.94 | 4.90 |
| Dr Reddy's Laboratories Ltd | 29.41bn | 4.72bn | 91.38bn | 26.94k | 19.37 | -- | 14.41 | 3.11 | 66.81 | 66.81 | 416.15 | -- | -- | -- | -- | 12,871,960.00 | -- | 12.15 | -- | 16.94 | 65.76 | 66.18 | 15.92 | 15.81 | -- | 19.79 | -- | 14.69 | 16.54 | 13.26 | 1.38 | 22.84 | 41.26 | 9.86 |
| Cipla Ltd | 24.04bn | 3.85bn | 92.57bn | 30.31k | 24.02 | -- | 19.61 | 3.85 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Elanco Animal Health Inc | 36.80bn | -1.81bn | 96.54bn | 9.40k | -- | 1.89 | 27.61 | 2.62 | -0.4848 | -0.4848 | 9.53 | 13.17 | 0.3631 | 1.28 | 5.62 | 501,595.80 | -1.79 | -2.26 | -2.01 | -2.53 | 54.99 | 55.59 | -4.92 | -7.41 | 1.08 | 1.15 | 0.3803 | -- | 6.22 | 7.59 | -168.64 | -- | -2.35 | -- |
| BridgeBio Pharma Inc | 3.92bn | -5.66bn | 97.64bn | 834.00 | -- | -- | -- | 24.92 | -3.78 | -3.78 | 2.62 | -10.71 | 0.5412 | -- | 6.97 | 602,009.60 | -79.01 | -76.52 | -105.26 | -96.54 | 95.82 | 96.16 | -145.98 | -340.73 | 2.68 | -2.17 | 4.29 | -- | 126.26 | 127.44 | -35.31 | -- | 4.99 | -- |
| Neurocrine Biosciences Inc | 22.33bn | 3.74bn | 102.72bn | 2.00k | 28.12 | 4.04 | 25.87 | 4.60 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| CSPC Pharmaceutical Group Ltd | 29.79bn | 4.62bn | 106.24bn | 19.27k | 22.87 | -- | 49.93 | 3.57 | 0.4031 | 0.4031 | 2.60 | -- | -- | -- | -- | 1,392,061.00 | -- | 14.64 | -- | 19.49 | 66.23 | 72.50 | 15.54 | 19.11 | -- | -- | -- | 41.10 | -7.76 | 5.59 | -26.31 | 3.11 | 4.76 | 21.28 |
| Sino Biopharmaceutical Ltd | 34.74bn | 4.43bn | 107.12bn | 23.06k | 23.26 | 2.69 | 11.60 | 3.08 | 0.2455 | 0.2438 | 1.92 | 2.12 | 0.4317 | 2.83 | 3.98 | 1,424,840.00 | 9.56 | 12.16 | 18.52 | 20.91 | 81.77 | 80.75 | 22.15 | 26.50 | 1.28 | -- | 0.2071 | 27.19 | 10.18 | 3.56 | 3.93 | -7.01 | -7.91 | 6.66 |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 11.06bn | 2.74bn | 108.37bn | 2.84k | 39.60 | 6.62 | -- | 9.80 | 4.01 | 4.01 | 16.21 | 23.99 | 0.5515 | 1.15 | 11.11 | 3,444,842.00 | 13.60 | 18.53 | 16.58 | 23.24 | 36.98 | 45.91 | 24.65 | 28.42 | 2.12 | -- | 0.0658 | 42.26 | 7.25 | 13.52 | 6.42 | 16.72 | 74.81 | 29.36 |
| Swedish Orphan Biovitrum AB (publ) | 23.78bn | 402.60m | 115.12bn | 1.89k | 294.88 | 3.50 | 34.51 | 4.84 | 1.30 | 1.30 | 81.42 | 109.12 | 0.3953 | 1.28 | 5.11 | 14,956,040.00 | 0.6663 | 3.92 | 0.8337 | 5.04 | 78.89 | 77.84 | 1.69 | 10.91 | 0.585 | 9.61 | 0.2336 | 0.00 | 8.50 | 13.10 | -87.70 | -31.82 | -3.93 | -- |
| Sichuan Biokin Pharmaceutical Co Ltd | 2.52bn | -964.13m | 115.50bn | 2.52k | -- | 14.24 | -- | 45.87 | -2.14 | -2.14 | 5.54 | 17.37 | 0.2309 | 1.44 | 2.31 | 883,003.90 | -8.84 | 27.12 | -11.31 | 47.59 | 89.15 | 86.86 | -38.29 | 29.03 | 5.23 | -- | 0.3446 | 0.00 | 936.31 | 37.00 | 575.02 | 243.69 | 31.86 | -- |
Data as of Mar 05 2026. Currency figures normalised to CSPC Pharmaceutical Group Ltd's reporting currency: Hong Kong Dollar HKD
14.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 320.13m | 2.78% |
| UBS Asset Management (Europe) SAas of 20 Jun 2025 | 226.26m | 1.96% |
| UBS Asset Management Switzerland AGas of 20 Jun 2025 | 164.61m | 1.43% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 161.97m | 1.41% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 156.48m | 1.36% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 154.99m | 1.35% |
| BlackRock Fund Advisorsas of 23 Sep 2024 | 139.21m | 1.21% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Dec 2025 | 119.42m | 1.04% |
| Hang Seng Investment Management Ltd.as of 06 Feb 2026 | 99.80m | 0.87% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 95.95m | 0.83% |
More ▼
Data from 30 Jun 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
